| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib inhibits BCR-ABL tyrosine kinase by blocking its ATP-binding site, which disrupts the kinase's ability to phosphorylate substrates involved in cell growth and division, specific to CML pathogenesis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits EGFR tyrosine kinase by binding to its ATP-binding site, preventing autophosphorylation and subsequent activation of downstream signaling pathways involved in cell proliferation, specific to EGFR-mutated lung cancers. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome's chymotrypsin-like activity, leading to the accumulation of polyubiquitinated proteins, which induces cell cycle arrest and apoptosis, specific to multiple myeloma and other malignancies. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits Raf kinases (part of the MAPK signaling pathway) and several receptor tyrosine kinases involved in angiogenesis (VEGFR and PDGFR), affecting tumor cell proliferation and blood supply, specific to renal and liver cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus inhibits mTOR, a key protein in a cellular signaling pathway that regulates cell growth, proliferation, and survival, specific to cancers like renal cell carcinoma where mTOR is dysregulated. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib irreversibly binds to Bruton's tyrosine kinase, inhibiting B-cell receptor signaling, which is critical for B-cell survival and proliferation, specific to CLL and other B-cell malignancies. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 targets and inhibits Bcl-2, a protein that prevents apoptosis in cancer cells, leading to cell death, specific to CLL and other hematologic malignancies. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib inhibits PARP enzymes, which play a role in DNA repair, leading to accumulation of DNA damage and cell death, specific to BRCA-mutated cancers. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 inhibits CDK4 and CDK6, leading to cell cycle arrest at the G1 phase, specific to ER-positive, HER2-negative breast cancer. | ||||||